Hikma Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Hikma Pharmaceuticals CEO'su Riad Mishlawi, Sep2023 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 1.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.5% maaş ve 78.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.06% ine doğrudan sahiptir ve bu hisseler £ 2.47M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.2 yıl ve 5.4 yıldır.
Anahtar bilgiler
Riad Mishlawi
İcra Kurulu Başkanı
US$1.6m
Toplam tazminat
| CEO maaş yüzdesi | 21.5% |
| CEO görev süresi | 1.2yrs |
| CEO sahipliği | 0.06% |
| Yönetim ortalama görev süresi | 1.2yrs |
| Yönetim Kurulu ortalama görev süresi | 5.4yrs |
Son yönetim güncellemeleri
Recent updates
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$285m |
| Mar 31 2024 | n/a | n/a | US$238m |
| Dec 31 2023 | US$2m | US$333k | US$190m |
Tazminat ve Piyasa: Riad 'nin toplam tazminatı ($USD 1.55M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.40M ).
Tazminat ve Kazançlar: Riad şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.
CEO
Riad Mishlawi (60 yo)
1.2yrs
Görev süresi
US$1,552,833
Tazminat
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 17.3yrs | US$3.57m | 0.38% £ 15.8m | |
| CEO & Director | 1.2yrs | US$1.55m | 0.060% £ 2.5m | |
| Executive Vice Chairman & President of MENA | 19.2yrs | US$2.84m | 0.63% £ 25.8m | |
| Chief Financial Officer | 13.8yrs | Veri yok | 0.20% £ 8.4m | |
| Chief Information Officer | no data | Veri yok | Veri yok | |
| Associate Director of Investor Relations | no data | Veri yok | Veri yok | |
| General Counsel | no data | Veri yok | Veri yok | |
| Executive Vice President of Corporate Development and M&A | 10.7yrs | Veri yok | 0.26% £ 10.6m | |
| Chief People Officer | 1.2yrs | Veri yok | Veri yok | |
| Executive Vice President of Strategic Planning & Global Affairs | 6.8yrs | Veri yok | Veri yok | |
| President of Injectables Business | 1.2yrs | Veri yok | Veri yok | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | less than a year | Veri yok | Veri yok |
1.2yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim: HIK 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 17.3yrs | US$3.57m | 0.38% £ 15.8m | |
| CEO & Director | 1.2yrs | US$1.55m | 0.060% £ 2.5m | |
| Executive Vice Chairman & President of MENA | 19.2yrs | US$2.84m | 0.63% £ 25.8m | |
| Senior Independent Non-Executive Director | 2yrs | US$149.27k | Veri yok | |
| Independent Non-Executive Director | 8.1yrs | US$176.38k | 0.0032% £ 131.7k | |
| Independent Non-Executive Director | 8.7yrs | US$159.69k | 0.0016% £ 65.0k | |
| Non-Executive Director | 19.1yrs | US$116.72k | 0.52% £ 21.6m | |
| Independent Non-Executive Director | 4.5yrs | US$149.85k | 0.0020% £ 83.5k | |
| Independent Non-Executive Director | 2yrs | US$127.05k | 0.00045% £ 18.5k | |
| Independent Non-Executive Director | 5.4yrs | US$134.68k | 0.00050% £ 20.6k | |
| Chairman of West-ward Pharmaceuticals | no data | Veri yok | Veri yok | |
| Independent Non-Executive Director | 2.1yrs | US$124.98k | Veri yok |
5.4yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HIK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).